Standard- and high-dose etoposide, ifosfamide, carboplatin, and epirubicin in 100 patients with small-cell lung cancer: A mature follow-up report

• Published in: Annals of oncology Vol. 10; no. 5; pp. 561 - 567
• Main Authors: Fetscher, S., Brugger, W., Engelhardt, R., Kanz, L., Hasse, J., Frommhold, H., Lange, W., Mertelsmann, R.
• Format: Journal Article
• Language: English
• Published: Oxford Oxford University Press 01.05.1999
• Subjects: Adult; Aged; Antineoplastic agents; Antineoplastic Combined Chemotherapy Protocols - administration & dosage; Biological and medical sciences; Carboplatin - administration & dosage; Carcinoma, Small Cell - drug therapy; Carcinoma, Small Cell - mortality; Carcinoma, Small Cell - surgery; Chemotherapy; Cisplatin - administration & dosage; Disease-Free Survival; Epirubicin - administration & dosage; Etoposide - administration & dosage; Female; Follow-Up Studies; hematopoietic growth-factor support; high-dose chemotherapy; Humans; Ifosfamide - administration & dosage; Lung Neoplasms - drug therapy; Lung Neoplasms - mortality; Lung Neoplasms - surgery; Male; Medical sciences; Middle Aged; Neoplasms, Second Primary - etiology; peripheral blood stem-cell transplantation; Pharmacology. Drug treatments; small-cell lung cancer; treatment toxicity and mortality; Antineoplastic agent; Intravenous administration; Toxicity; Bronchopulmonary; Phase II trial; Bronchus disease; Advanced stage; Epirubicin; Small cell carcinoma; High dose; Platinum II Complexes; Human; Lung disease; Drug combination; Respiratory disease; Ifosfamide; Treatment efficiency; Etoposide; Tolerance; Malignant tumor; Podophyllotoxine derivatives; Chemotherapy; Oxazaphosphinane derivatives; Treatment; Nitrogen mustard; Carboplatin; Phase I trial; Anthracyclins
• ISSN: 0923-7534; 1569-8041
• DOI: 10.1023/A:1026453922931

Background: We conducted a phase I–II trial to assess the feasibility and activity of a combination chemotherapy regimen with etoposide, ifosfamide, cisplatin or carboplatin, and epirubicin in limited-disease (LD, stages I-IIIB) and extensive-stage (ED, stage IV) small-cell lung cancer (SCLC). Patients and methods: Standard-dose chemotherapy (SDC) consisting of etoposide (500 mg/m2), ifosfamide (4000 mg/m2), cisplatin (50 mg/m2) and epirubicin (50 mg/m2) (VIP-E), followed by granulocyte colony-stimulating factor (G-CSF), was given to 100 patients with SCLC. Thirty patients with qualifying responses to VIP-E proceeded to high-dose chemotherapy (HDC) with autologous peripheral blood stem-cell transplantation (PBSCT) after etoposide (1,500 mg/m2), ifosfamide (12,000 mg/m2), carboplatin (750 mg/m2) and epirubicin (150 mg/m2) (VIC-E) conditioning. Results of standard-dose VIP-E: Ninety-seven patients were evaluable for response. The objective response rate was 81% in LD SCLC (33% CR, 48% PR; excluding patients in surgical CR) and 77% in ED SCLC (18% CR, 58% PR). The treatment-related mortality (TRM) of SDC was 2%. Two additional patients in CR from their SCLC developed secondary non-small-cell lung cancers (NSCLC), and both were cured by surgery. The median survival was 19 months in LD SCLC and 6 months in ED SCLC. The five-year survivals were 36% in LD and 0% in ED SCLC. Results of high-dose VIC-E: HDC was feasible in 16% of ED-, and 58% of LD-patients. All HDC patients (n = 30) improved or maintained prior responses. Four patients died of early treatment-related complications (TRM 13%). Two additional patients in CR from their SCLC developed secondary malignancies (esophageal cancer, secondary chronic myeloge-nous leukemia). The median survivals were 26 months in LD SCLC, and 8 months in ED SCLC. The five-year survival was 50% in LD and 0% in ED SCLC. Conclusions: Despite high response rates, survival after VIP-E SDC and VIC-E HDC in patients with ED SCLC is not superior to that achieved with less toxic traditional regimens. The high five-year survival rates achieved with these protocols in LD SCLC probably reflect both patient selection (high proportion of patients with prior surgical resection) and the high activity of our chemotherapy regimen in combination with radiotherapy. A study comparing protocols using simultaneous radiation therapy and chemotherapy, and other dose-escalated forms of SDC with HDC is needed to further define the role of this treatment modality in SCLC. Given the high rate of secondary malignancies observed in patients in CR > 2 years in our study, close follow-up and early treatment of these neoplasms may contribute to maintaining overall survival in patients with SCLC.